Fig. 3
GSTM3TV2 enhances gemcitabine resistance in vivo and in vitro.
a Overexpression of GSTM3TV2 in AsPC-1 cells decreased the inhibitory effects of gemcitabine as determined by detecting cell viability. b Overexpression of GSTM3TV2 in AsPC-1 cells decreased gemcitabine-induced cell death as determined by detecting apoptosis rates. c Knockdown GSTM3TV2 in gemcitabine-resistant MIAPaCa-2/GR cells increased chemosensitivity as determined by detecting cell viability. d Knockdown GSTM3TV2 in gemcitabine-resistant MIAPaCa-2/GR cells increased gemcitabine-induced cell death determined by detecting apoptosis rates. e Total number of tumours resected from mice 28 days treated with gemcitabine of AsPC-1 cells stable expression with GSTM3TV2 (Rv-AsPC-1-GSTM3TV2) or NC (Rv-AsPC-1-NC). f The tumourigenesis capability of Rv-AsPC-1-GSTM3TV2 cells and Rv-AsPC-1-NC cells were examined in vivo by measuring the tumour volume and tumour weight. The data are presented as the mean ± SD (Student’s t test; asterisk indicates P < 0.05)